BioSpace News Archive

ASA, The Bladder Cancer Company, announces that President and Chief Executive Officer, Dan Schneider and Chief Financial Officer, Erik Dahl will present a corporate overview and host 1-on-1 meetings with investors at the Piper Sandler 33rd Annual Healthcare conference, being held virtually November 29 through December 2, 2021.

Intrauterine contraceptive devices appear to have systemic effects on the body like those of hormone replacement therapy, according to a breast MRI study being presented next week at the annual meeting of the Radiological Society of North America.

GenSight Biologics announced that it will host a webcast with Dr. Sean P. Donahue, MD, PhD, of Vanderbilt University on outcomes among six Leber Hereditary Optic Neuropathy patients treated bilaterally with LUMEVOQ® under an FDA-approved compassionate use protocol.

Adolescents and young adults with post-concussive symptoms who suffered three to five concussions showed disruption in the default mode network, an interconnected network of brain regions involved in wakeful rest and internal thoughts.

ObsEva SA, a biopharmaceutical company developing and commercializing novel therapies to improve women’s reproductive health, announced that Stephanie Brown has been selected to join its Board of Directors and will be proposed for election at the 2022 Annual General Meeting.

illumigyn, the world’s first remote gynecological imaging platform, announced today that it signed a new distribution agreement with Peramare Enterprises to deploy 20,000 Gynescopes™ systems across Africa.

MediciNova, Inc. announced that MediciNova’s research collaborator, Justin Lathia PhD, Co-Director of the Brain Tumor Research and Therapeutic Development Center of Excellence at Cleveland Clinic Lerner Research Institute presented new data regarding MN-166 from a glioblastoma animal model study at the 26th Annual Meeting of the Society for Neuro-Oncology held November 18 - 21, 2021 in Boston.

Merck (NYSE: MRK), known as MSD outside the United States and Canada, today announced the successful completion of the acquisition of Acceleron Pharma Inc. (Nasdaq: XLRN).

Eagle Pharmaceuticals to Present at Piper Sandler 33rd Annual Healthcare Conference 2021

Imara Inc. (Nasdaq: IMRA), today announced a change to the primary endpoint for the Ardent clinical trial, a Phase 2b study of tovinontrine (IMR-687) in patients with sickle cell disease (SCD), based on the recommendation of the U.S. Food and Drug Administration (FDA).